Home › Heart Valve Diseases › Pennsylvania › Philadelphia
Heart Valve Diseases clinical trials in Philadelphia, PA
4 studies for Heart Valve Diseases are looking for participants at sites in and around Philadelphia (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Recruiting
- Lankenau Medical Center, Wynnewood · 7 mi away
Abbott Structural Heart Device Registry
RecruitingObservational study
- University of Pennsylvania, Philadelphia
The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR
Recruiting
- University of Pennsylvania, Philadelphia
- Lankenau Institute of Medical Research, Wynnewood · 7 mi away
CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting
RecruitingObservational study
- University of Pennsylvania, Philadelphia
About Heart Valve Diseases
Heart valve disease happens when one or more of your heart valves do not open or close correctly. This can affect your blood flow and strain your heart.
More about Heart Valve Diseases on MedlinePlus
Heart Valve Diseases trials in other cities
- New York City, NY11 studies
- Cleveland, OH10 studies
- Chicago, IL5 studies
- Cincinnati, OH5 studies
- Phoenix, AZ5 studies
- Minneapolis, MN5 studies
- Atlanta, GA4 studies
- Pittsburgh, PA4 studies
- Houston, TX4 studies
- Boston, MA4 studies
- Thousand Oaks, CA3 studies
- Ann Arbor, MI3 studies
Other studies in Philadelphia
- Cancer (all types)59 studies
- Breast Cancer56 studies
- Non-Small Cell Lung Cancer51 studies
- Metastatic Cancer46 studies
- Prostate Cancer44 studies
- Colorectal Cancer44 studies
- Ovarian Cancer44 studies
- Lung Cancer36 studies
- Acute Myeloid Leukemia34 studies
- Heart Failure31 studies
- Endometrial Cancer28 studies
- Depression26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.